Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

The NFKBIE gene, which encodes the NF-κB inhibitor IκBε, is mutated in 3-7% of patients with chronic lymphocytic leukemia (CLL). The most recurrent alteration is a 4-bp frameshift deletion associated with NF-κB activation in leukemic B cells and poor clinical outcome. To study the functional consequences of NFKBIE gene inactivation, both in vitro and in vivo, we engineered CLL B cells and CLL-prone mice to stably down-regulate NFKBIE expression and investigated its role in controlling NF-κB activity and disease expansion. We found that IκBε loss leads to NF-κB pathway activation and promotes both migration and proliferation of CLL cells in a dose-dependent manner. Importantly, NFKBIE inactivation was sufficient to induce a more rapid expansion of the CLL clone in lymphoid organs and contributed to the development of an aggressive disease with a shortened survival in both xenografts and genetically modified mice. IκBε deficiency was associated with an alteration of the MAPK pathway, also confirmed by RNA-sequencing in NFKBIE-mutated patient samples, and resistance to the BTK inhibitor ibrutinib. In summary, our work underscores the multimodal relevance of the NF-κB pathway in CLL and paves the way to translate these findings into novel therapeutic options. © 2024. The Author(s), under exclusive licence to Springer Nature Limited.

Citation

Jessica Bordini, Chiara Lenzi, Michela Frenquelli, Alessia Morabito, Athanasios Pseftogas, Daniela Belloni, Larry Mansouri, George Tsiolas, Eleonora Perotta, Pamela Ranghetti, Francesca Gandini, Francesca Genova, Daniel Hägerstrand, Georgios Gavriilidis, Sofoklis Keisaris, Nikolaos Pechlivanis, Frederic Davi, Neil E Kay, Anton W Langerak, Sarka Pospisilova, Lydia Scarfò, Antonios Makris, Fotis E Psomopoulos, Kostas Stamatopoulos, Richard Rosenquist, Alessandro Campanella, Paolo Ghia. IκBε deficiency accelerates disease development in chronic lymphocytic leukemia. Leukemia. 2024 Jun;38(6):1287-1298

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 38575671

View Full Text